EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Retrospective Evaluation of Dual Specialty Ports in Therapeutic Apheresis

Mugtaba Swar-Eldahab, Barnabas Obeng-Gyasi iD, Paul Haste, Matthew Krosin

Journal of Clinical Apheresis · 2026

DOI: 10.1002/jca.70126 ↗

At a glance

Journal article in Journal of Clinical Apheresis, 2026. Written by Mugtaba Swar-Eldahab and 3 co-authors. Institution: Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana, USA. Major MEDLINE topics: Blood Component Removal, Vascular Access Devices. Cited 1 times so far (Crossref); 18 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Dual specialty ports were evaluated for safety and efficacy in therapeutic apheresis by analyzing outcomes across 97 port placement events in 88 patients, focusing on two configurations: dual Bard PowerFlow (BP2) and a combination of Bard PowerFlow with AngioDynamics SmartPort (BP + AD). This retrospective cohort study was conducted at a tertiary care center from December 2017 to July 2024 and included 97 port placement events (194 total ports) across 88 patients with conditions such as bronchiolitis obliterans, sickle cell disease, myasthenia gravis, and graft‐versus‐host disease who required therapeutic apheresis. Measured outcomes included port revisions, removals, total port days, and complications. The BP2 configuration was used in 43 events (44.3%), and the BP + AD configuration in 54 events (55.7%). Common indications included bronchiolitis obliterans (40.2%), sickle cell disease (17.5%), myasthenia gravis (12.4%), and GVHD (12.4%). Revisions were necessary in 5.7% of ports due to mechanical issues or thrombosis, while 36.1% of ports were removed, mainly due to infection/bacteremia or completion of therapy. Port functionality ranged from 22 to 2080 days, with a mean of 564 days. The mortality rate during follow‐up was 21.6%. Dual specialty ports demonstrate viable long‐term access for therapeutic apheresis in selected patients, with functionality extending from months to years. Success appears highly dependent on patient selection, with infection risks particularly notable in immunocompromised populations. These findings support the use of specialty ports as an alternative to traditional tunneled catheters, particularly for those with preserved immune function requiring chronic therapy.

Subjects

MeSH terms (MEDLINE)

Blood Component RemovalVascular Access DevicesHumansRetrospective StudiesFemaleMaleAdultMiddle AgedMyasthenia GravisAdolescentAgedEquipment DesignYoung Adult

Author keywords

PowerFlow technologyclinical outcomesimplantable portsport complicationsquality of lifetherapeutic apheresisvascular access devices

Authors and institutions

  • Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana, USA.

ORCID profiles: Barnabas Obeng-Gyasi

Cite

APA

Swar-Eldahab, M., Obeng-Gyasi, B., Haste, P., & Krosin, M. (2026). Retrospective Evaluation of Dual Specialty Ports in Therapeutic Apheresis. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.70126

Vancouver

Swar-Eldahab M, Obeng-Gyasi B, Haste P, Krosin M. Retrospective Evaluation of Dual Specialty Ports in Therapeutic Apheresis. Journal of Clinical Apheresis. 2026. doi:10.1002/jca.70126

BibTeX
@article{SwarEldahab2026,
  author = {Swar-Eldahab, Mugtaba and Obeng-Gyasi, Barnabas and Haste, Paul and Krosin, Matthew},
  title = {Retrospective Evaluation of Dual Specialty Ports in Therapeutic Apheresis},
  journal = {Journal of Clinical Apheresis},
  year = {2026},
  doi = {10.1002/jca.70126}
}
Start for free →